Product marketed as dietary supplement contains drug ingredient Tadalafil, which may interact with nitrates found in some prescription drugs and lower blood pressure to dangerous levels.
Neurological Devices Panel of the Medical Devices Advisory Committee Meeting Announcement (March 23, 2012)February 12, 2012 11:31 pm | by U.S. Food & Drug Administration | News | Comments
This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.
Hand-held Dental X-Ray Units: FDA Safety Communication - Unreviewed Products May Not Be Safe or EffectiveFebruary 10, 2012 5:31 pm | by U.S. Food & Drug Administration | News | Comments
Products could potentially expose users and patients to unnecessary and potentially harmful X-rays.
Products intended for use in the eye that are non-sterile have the potential to cause eye infections, which may be sight threatening. Also, nasal solutions that are not sterile could lead to a respiratory infection.
Smith & Nephew has agreed to pay the U.S. government $22.2 million to settle allegations it bribed Greek doctors to encourage the use of its orthopedic products.
The device industry and congressional allies are considering using the Medical Device User Fee Act (MDUFA) reauthorization package or other legislation as a vehicle to repeal the medical device tax before it can take effect in January 2013.
The Gastroenterology-Urology Devices Panel reviews and evaluates data concerning the safety and effectiveness of marketed and investigational gastroenterology, urology and nephrology devices...
Victrelis (boceprevir) and Ritonavir-Boosted Human Immunodeficiency Virus (HIV) Protease Inhibitor Drugs: Drug Safety Communication - Drug InteractionsFebruary 9, 2012 7:31 am | by U.S. Food & Drug Administration | News | Comments
Interactions between Victrelis and ritonavir-boosted atazanavir, lopinavir, and darunavir can potentially reduce the effectiveness of these medicines when co-administered.
SAN JOSE, Calif.--(BUSINESS WIRE)--Alverix announced today that BD (Becton, Dickinson and Company) has received approval from the Japanese Ministry of Health, Labour, and Welfare (MHLW) for the BD Veritorâ„¢ System Flu A+B Test. The BD Veritor System was developed...
AUSTIN, Tex.-Despite a tepid economy, medical device manufacturers' international sales growth rates continued to outpace their domestic business in 2011, demonstrating the increasingly global nature of the industry. According to a new survey of more than 2,600 medical device industry...
Survey: Smaller Medical Device Firms Plan to Increase Prices and Lower Costs to Offset US Excise TaxFebruary 9, 2012 4:34 am | News | Comments
AUSTIN, Tex.-According to a new industry survey conducted by global consultancy Emergo Group, medical device manufacturers plan to increase prices for their products in order to offset the effects of a proposed 2.3% excise tax on all device sales in the US set to take effect in 2013.
Proton Pump Inhibitors (PPIs) - Drug Safety Communication: Clostridum Difficile-Associated Diarrhea (CDAD) Can be Associated With Stomach Acid DrugsFebruary 8, 2012 5:30 am | by U.S. Food & Drug Administration | News | Comments
Symptoms may include watery stool, abdominal pain, and fever. Patients may go on to develop more serious intestinal conditions.
The Neurological Devices Panel reviews and evaluates data concerning the safety and effectiveness of marketed and investigational in vitro devices for use in clinical laboratory medicine including clinical and molecular genetics ...
GAO Investigation Finds Lack of Price Transparency in Medical Device Marketplace May Drive up Costs for Hospitals and MedicareFebruary 6, 2012 5:47 am | News | Comments
Washington, DC â€“ The Healthcare Supply Chain Association (HSCA) today applauded the U.S. Government Accountability Office for its new report, Lack of Price Transparency May Hamper Hospitals' Ability to Be Prudent Purchasers of Implantable Medical Devices, which found that...
Recalled products pose significant risk to patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke.
During packaging and labeling, tablets from one product type may have carried over into packaging of another product.
Use of an inhaled product with glass particles has the potential to cause choking which could be life-threatening.
Summary Information for: Therapy Cool Path Duo? Ablation Catheter, Safire BLU Duo? Ablation Catheter, and IBI1500T9-CP V1.6 Cardiac Ablation GeneratorFebruary 2, 2012 11:31 am | by U.S. Food & Drug Administration | News | Comments
Labeling, Approval Order, and Summary of Safety and Effectiveness for Therapy Cool Path Duo? Ablation Catheter, Safire BLU Duo? Ablation Catheter, and IBI1500T9-CP V1.6 Cardiac Ablation Generator (P110016).
Consumer Information on: Therapy Cool Path Duo? Ablation Catheter, Safire BLU Duo? Ablation Catheter, and IBI1500T9-CP V1.6 Cardiac Ablation Generator - P110016February 2, 2012 11:30 am | by U.S. Food & Drug Administration | News | Comments
The Therapy Cool Path Duo? Ablation Catheter or the Safire BLU Duo? Ablation Catheter is a steerable, deflectable, irrigated catheter (a long, thin, flexible tube) used to treat a certain kind of abnormal heart rhythm (arrhythmia2) called typical atrial..
Extended Sunshine Act Deadline Provides Extra Time for Pharma, Biotech and Device Companies to Track and Report Physician PaymentsFebruary 1, 2012 5:56 am | News | Comments
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--As the industry awaits the release of the delayed Sunshine Act guidelines, pharmaceutical and medical device companies are benefiting from the extra time by reviewing current physician payment reporting structures...
The FDA and representatives from the medical device industry have reached an agreement in principle on proposed recommendations for the third reauthorization of a medical device user fee program. The recommendations would authorize the FDA to collect $595 million in user fees...
Lo/Ovral-28 (Norgestrel/EthinylEstradiol) Tablets: Recall - Possibility of Inexact Tablet Counts or Out of Sequence TabletsFebruary 1, 2012 4:30 am | by U.S. Food & Drug Administration | News | Comments
Oral contraceptive daily regimen may be incorrect and could leave women without adequate contraception, and at risk for unintended pregnancy.
Consequences of using the incorrectly labeled product may result in high potassium blood levels (hyperkalemia) or high sodium levels in the blood (hypernatremia).
Potential adverse events after intravenous administration of solutions containing particulates may include emboli and result in disruption of blood flow, causing tissue/organ damage.
CDRH’s 2012 priorities include a strong focus on innovation and the device approval process, a strategic report shows.